Troy Edward Wilson Buys Another $1.5 Million Of Kura Oncology Shares

The latest purchases bring the Kura chief executive's stock purchases since August 18 to $2.7 million.

Share
Troy Edward Wilson Buys Another $1.5 Million Of Kura Oncology Shares

Troy Edward Wilson, president and CEO of Kura Oncology, which develops and sells targeted cancer medicines, bought another $1.5 million of its stock Friday and Monday. His SEC insider-trading filing, filed Monday, puts the latest purchases at 200,000 shares—about 14% of his reported holdings after the trades.

Buying Below His August Price

Wilson paid an average of $7.52 per share for the latest purchases, below the roughly $12.39 he paid on August 24. That earlier purchase covered 100,000 shares and cost $1.2 million.

Friday's purchase accounted for 98,881 shares at an average $7.63. He bought another 101,119 shares Monday at an average $7.42.

KURA shares closed Monday at $7.09, below his latest average purchase price. The stock was down about 32% for the year at Monday's close.

SEC filing history covering August 18 through Monday shows two open-market purchase filings by Wilson: the August transaction and the latest filing. Together, they covered 300,000 shares costing $2.7 million.

A 1.4 Million-Share Holding

Wilson reported 1,414,650 shares after the purchases, with an estimated value of $10.0 million at Monday's close. He owns 635,456 directly and holds 779,194 through One Fish Two Fish Revocable Trust and Lorax Charitable Remainder Unitrust.

Kura's commercial medicine, KOMZIFTI, is an oral ziftomenib treatment sold in the United States for adults with acute myeloid leukemia that has returned or resisted treatment. Eligible patients have a susceptible nucleophosmin 1 mutation and no satisfactory alternative treatment options.

Kura records all US KOMZIFTI sales. It splits commercialization profits and losses equally with Kyowa Kirin, the company responsible for commercialization outside the United States.

Its research includes ziftomenib combinations for leukemia and gastrointestinal tumors. Kura is also studying darlifarnib combinations for solid tumors, including kidney, lung, colorectal and pancreatic cancers.

Sources

More on Kura Oncology

All Kura Oncology (KURA) coverage →